FGF/FGFR signaling in bone formation: Progress and perspectives

Growth Factors

Volumn 30, Issue 2, 2012, Pages 117-123

  Marie, Pierre J ^a   Miraoui, Hichem ^a   Séveère, Nicolas ^a  

^a INSERM   (France)

Author keywords

bone formation; FGF; FGFR; signaling

Indexed keywords

ALPHA5 INTEGRIN; BONE MORPHOGENETIC PROTEIN; CASPASE 3; CASPASE 9; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 18; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; TRANSCRIPTION FACTOR TWIST;

ACROCEPHALOSYNDACTYLY; BONE DYSPLASIA; CELL DIFFERENTIATION; CELL SURVIVAL; CRANIOFACIAL SYNOSTOSIS; ENZYME ACTIVATION; GENE MUTATION; GENOMICS; HUMAN; MOLECULAR INTERACTION; OSSIFICATION; OSTEOBLAST; OSTEOGLOPHONIC DYSPLASIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; CELL DIFFERENTIATION; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; MICE; OSTEOBLASTS; OSTEOGENESIS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84858960891     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2012.656761     Document Type: Review

References (81)

1. Ambrosetti D, Holmes G, Mansukhani A, Basilico C. 2008. Fibroblast growth factor signaling uses multiple mechanisms to inhibit Wnt-induced transcription in osteoblasts. Mol Cell Biol 28(15):4759-4771.
2. Baroni T, Carinci P, Lilli C, Bellucci C, Aisa MC, Scapoli L, Volinia S, Carinci F, Pezzetti F, Calvitti M, Farina A, Conte C, Bodo M. 2005. P253R fibroblast growth factor receptor-2 mutation induces RUNX2 transcript variants and calvarial osteoblast differentiation. J Cell Physiol 202(2):524-535. (Pubitemid 40041324)
3. Basu-Roy U, Ambrosetti D, Favaro R, Nicolis SK, Mansukhani A, Basilico C. 2011. The transcription factor Sox2 is required for osteoblast self-renewal. Cell Death Differ 17(8):1345-1353.
4. Beenken A, Mohammadi M. 2009. The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov 8(3): 235-253.
5. Behr B, Sorkin M, Manu A, Lehnhardt M, Longaker MT, Quarto N. 2011. Fgf-18 is required for osteogenesis but not angiogenesis during long bone repair. Tissue Eng Part A 17(15-16):2061-2069.
6. Bresnick S, Schendel S. 1995. Crouzon's disease correlates with low fibroblastic growth factor receptor activity in stenosed cranial sutures. J Craniofac Surg 6(3):245-248.
7. Choi KY, Kim HJ, Lee MH, Kwon TG, Nah HD, Furuichi T, Komori T, Nam SH, Kim YJ, Ryoo HM. 2005. Runx2 regulates FGF2-induced Bmp2 expression during cranial bone development. Dev Dyn 233(1):115-121. (Pubitemid 40548029)
8. Choi SC, Kim SJ, Choi JH, Park CY, Shim WJ, Lim DS. 2008. Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways. Stem Cells Dev 17(4):725-736.
9. Connerney J, Andreeva V, Leshem Y, Mercado MA, Dowell K, Yang X, Lindner V, Friesel RE, Spicer DB. 2008. Twist1 homodimers enhance FGF responsiveness of the cranial sutures and promote suture closure. Dev Biol 318(2):323-334.
10. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. 2005. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 16(2):233-247. (Pubitemid 40616120)
11. Debiais F, Lefevre G, Lemonnier J, Le Mee S, Lasmoles F, Mascarelli F, Marie PJ. 2004. Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -beta-catenin-independent signaling pathway. Exp Cell Res 297(1):235-246. (Pubitemid 38759576)
12. Dufour C, Guenou H, Kaabeche K, Bouvard D, Sanjay A, Marie PJ. 2008. FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt signaling and osteoblast survival. Bone 42(6):1032-1039.
13. Eswarakumar VP, Monsonego-Ornan E, Pines M, Antonopoulou I, Morriss-Kay GM, Lonai P. 2002. The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development 129(16):3783-3793. (Pubitemid 34994009)
14. Eswarakumar VP, Ozcan F, Lew ED, Bae JH, Tome F, Booth CJ, Adams DJ, Lax I, Schlessinger J. 2006. Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis. Proc Natl Acad Sci USA 103(49):18603-18608. (Pubitemid 44913457)
15. Fakhry A, Ratisoontorn C, Vedhachalam C, Salhab I, Koyama E, Leboy P, Pacifici M, Kirschner RE, Nah HD. 2005. Effects of FGF-2/-9 in calvarial bone cell cultures: Differentiation stage-dependent mitogenic effect, inverse regulation of BMP-2 and noggin, and enhancement of osteogenic potential. Bone 36(2):254-266. (Pubitemid 40283582)
16. Fanganiello RD, Sertie AL, Reis EM, Yeh E, Oliveira NA, Bueno DF, Kerkis I, Alonso N, Cavalheiro S, Matsushita H, Freitas R, Verjovski-Almeida S, Passos-Bueno MR. 2007. Apert p.Ser252Trp mutation in FGFR2 alters osteogenic potential and gene expression of cranial periosteal cells. Mol Med 13(7-8):422-442. (Pubitemid 47378145)
17. Fei Y, Xiao L, Doetschman T, Coffin DJ, Hurley MM. 2011. Fibroblast growth factor 2 stimulation of osteoblast differentiation and bone formation is mediated by modulation of the wnt signaling pathway. J Biol Chem 286(47):40575-40583.
18. Guenou H, Kaabeche K, Mee SL, Marie PJ. 2005. A role for fibroblast growth factor receptor-2 in the altered osteoblast phenotype induced by Twist haploinsufficiency in the Saethre- Chotzen syndrome. Hum Mol Genet 14(11):1429-1439. (Pubitemid 40823453)
19. Hamidouche Z, Fromigue O, Nuber U, Vaudin P, Pages JC, Ebert R, Jakob F, Miraoui H, Marie PJ. 2009. Autocrine fibroblast growth factor 18 mediates dexamethasone-induced osteogenic differentiation of murine mesenchymal stem cells. J Cell Physiol 224(2):509-515.
20. Hatch NE, Hudson M, Seto ML, Cunningham ML, Bothwell M. 2006. Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F. J Biol Chem 281(37):27292-27305. (Pubitemid 44401757)
21. Hurley MM, Marie PJ, Florkiewicz RZ. 2001. Fibroblast growth factor (FGF) and FGF receptor families in bone. In: Principles of Bone Biology, 2nd edition, vol. 1. Academic Press. USA, pp 825-851.
22. Hurley MM, Okada Y, Xiao L, Tanaka Y, Ito M, Okimoto N, Nakamura T, Rosen CJ, Doetschman T, Coffin JD. 2006. Impaired bone anabolic response to parathyroid hormone in Fgf2 - /- and Fgf2 + /- mice. Biochem Biophys Res Commun 341(4):989-994. (Pubitemid 43221763)
23. Jacob AL, Smith C, Partanen J, Ornitz DM. 2006. Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation. Dev Biol 296(2):315-328. (Pubitemid 44189342)
24. Kaabeche K, Guenou H, Bouvard D, Didelot N, Listrat A, Marie PJ. 2005. Cbl-mediated ubiquitination of alpha5 integrin subunit mediates fibronectin-dependent osteoblast detachment and apoptosis induced by FGFR2 activation. J Cell Sci 118(Pt 6):1223-1232. (Pubitemid 40528692)
25. Kaabeche K, Lemonnier J, Le Mee S, Caverzasio J, Marie PJ. 2004. Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation. J Biol Chem 279(35):36259-36267. (Pubitemid 39128962)
26. Kim HJ, Kim JH, Bae SC, Choi JY, Ryoo HM. 2003. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem 278(1):319-326.
27. Kim BG, Kim HJ, Park HJ, Kim YJ, Yoon WJ, Lee SJ, Ryoo HM, Cho JY. 2006. Runx2 phosphorylation induced by fibroblast growth factor-2/protein kinase C pathways. Proteomics 6(4): 1166-1174.
28. Lemonnier J, Delannoy P, Hott M, Lomri A, Modrowski D, Marie PJ. 2000. The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent down-regulation of FGFR-2 associated with premature calvaria osteoblast differentiation. Exp Cell Res 256(1):158-167. (Pubitemid 30211178)
29. Lemonnier J, Hay E, Delannoy P, Fromigue O, Lomri A, Modrowski D, Marie PJ. 2001. Increased osteoblast apoptosis in apert craniosynostosis: Role of protein kinase C and interleukin-1. Am J Pathol 158(5):1833-1842. (Pubitemid 32422948)
30. Liang H, Pun S, Wronski TJ. 1999. Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats. Endocrinology 140(12):5780-5788. (Pubitemid 30645367)
31. Liu Z, Xu J, Colvin JS, Ornitz DM. 2002. Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev 16(7):859-869. (Pubitemid 34280109)
32. Liu B, Yu HM, Hsu W. 2007. Craniosynostosis caused by Axin2 deficiency is mediated through distinct functions of beta-catenin in proliferation and differentiation. Dev Biol 301(1):298-308. (Pubitemid 44958400)
33. Liu S, Tang W, Fang J, Ren J, Li H, Xiao Z, Quarles LD. 2009. Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol 23(9):1505-1518.
34. Mansukhani A, Bellosta P, Sahni M, Basilico C. 2000. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol 149(6):1297-1308. (Pubitemid 30399682)
35. Mansukhani A, Ambrosetti D, Holmes G, Cornivelli L, Basilico C. 2005. Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J Cell Biol 168(7):1065-1076.
36. Marie PJ. 2003. Fibroblast growth factor signaling controlling osteoblast differentiation. Gene 316:23-32. (Pubitemid 37258340)
37. Marie PJ, Coffin JD, Hurley MM. 2005. FGF and FGFR signaling in chondrodysplasias and craniosynostosis. J Cell Biochem 96(5):888-896. (Pubitemid 41688715)
38. Marie PJ, Kaabeche K, Guenou H. 2008. Roles of FGFR2 and twist in human craniosynostosis: Insights from genetic mutations in cranial osteoblasts. Front Oral Biol 12:144-159.
39. Martin A, Liu S, David V, Li H, Karydis A, Feng JQ, Quarles LD. 2011. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 25(8):2551-2562.
40. Mathijssen IM, van Leeuwen JP, Vermeij-Keers C. 2000. Simultaneous induction of apoptosis, collagen type I expression and mineralization in the developing coronal suture following FGF4 and FGF2 application. J Craniofac Genet Dev Biol 20(3):127-136. (Pubitemid 32222599)
41. McDowell LM, Frazier BA, Studelska DR, Giljum K, Chen J, Liu J, Yu K, Ornitz DM, Zhang L. 2006. Inhibition or activation of Apert syndrome FGFR2 (S252W) signaling by specific glycosaminoglycans. J Biol Chem 281(11):6924-6930. (Pubitemid 43847454)
42. Miraoui H, Marie PJ. 2010a. Fibroblast growth factor receptor signaling crosstalk in skeletogenesis. Sci Signal 3(146):re9.
43. Miraoui H, Marie PJ. 2010b. Pivotal role of Twist in skeletal biology and pathology. Gene 468(1-2):1-7.
44. Miraoui H, Oudina K, Petite H, Tanimoto Y, Moriyama K, Marie PJ. 2009. Fibroblast growth factor receptor2 promotes osteogenic differentiation in mesenchymal cells via extracellular-related kinase and protein kinase C signalling. J Biol Chem 284(8):4897-4904.
45. Miraoui H, Ringe J, Häupl T, Marie PJ. 2010a. Increased EFG- and PDGFα-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis. Hum Mol Genet 19(9):1678-1689.
46. Miraoui H, Sévère N, Vaudin P, Pagès JC, Marie PJ. 2010b. Molecular silencing of twist1 enhances osteogenic differentiation of murine mesenchymal stem cells: implication of FGFR2 signalling. J Cell Biochem 110(5):1147-1154.
47. Moenning A, Jager R, Egert A, Kress W, Wardelmann E, Schorle H. 2009. Sustained platelet-derived growth factor receptor alpha signaling in osteoblasts results in craniosynostosis by over-activating the phospholipase C-gamma pathway. Mol Cell Biol 29(3):881-891.
48. Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, Doetschman T, Coffin JD, Hurley MM. 2000. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 105(8):1085-1093. (Pubitemid 30217693)
49. Nakamura Y, Tensho K, Nakaya H, Nawata M, Okabe T, Wakitani S. 2005. Low dose fibroblast growth factor-2 (FGF-2) enhances bone morphogenetic protein-2 (BMP-2)-induced ectopic bone formation in mice. Bone 36(3):399-407. (Pubitemid 40403838)
50. Nauman EA, Sakata T, Keaveny TM, Halloran BP, BikleDD. 2003. bFGF administration lowers the phosphate threshold for mineralization in bone marrow stromal cells. Calcif Tissue Int 73(2):147-152. (Pubitemid 37082361)
51. Ohbayashi N, Shibayama M, Kurotaki Y, Imanishi M, Fujimori T, Itoh N, Takada S. 2002. FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev 16(7):870-879. (Pubitemid 34280110)
52. Ornitz DM. 2005. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 16(2):205-213. (Pubitemid 40616117)
53. Ornitz DM, Marie PJ. 2002. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16(12):1446-1465. (Pubitemid 34686327)
54. Park J, Park OJ, Yoon WJ, Kim HJ, Choi KY, Cho TJ, Ryoo HM. 2012. Functional characterization of a novel FGFR2 mutation, E731K, in craniosynostosis. J Cell Biochem 113(2):457-464.
55. Perlyn CA, Morriss-Kay G, Darvann T, Tenenbaum M, Ornitz DM. 2006. A model for the pharmacological treatment of crouzon syndrome. Neurosurgery 59(1):210-215. (Pubitemid 44024379)
56. Raucci A, Bellosta P, Grassi R, Basilico C, Mansukhani A. 2008. Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways. J Cell Physiol 215(2):442-451. (Pubitemid 351468956)
57. Reinhold MI, Abe M, Kapadia RM, Liao Z, Naski MC. 2004. FGF18 represses noggin expression and is induced by calcineurin. J Biol Chem 279(37):38209-38219. (Pubitemid 39295968)
58. Rice DP, Aberg T, Chan Y, Tang Z, Kettunen PJ, Pakarinen L, Maxson RE, Thesleff I. 2000. Integration of FGF and TWIST in calvarial bone and suture development. Development 127(9): 1845-1855. (Pubitemid 30311788)
59. Rice R, Rice DP, Thesleff I. 2005. Foxc1 integrates Fgf and Bmp signalling independently of twist or noggin during calvarial bone development. Dev Dyn 233(3):847-852. (Pubitemid 40853461)
60. Sabbieti MG, Agas D, Xiao L, Marchetti L, Coffin JD, Doetschman T, Hurley MM. 2009. Endogenous FGF-2 is critically important in PTH anabolic effects on bone. J Cell Physiol 219(1):143-151.
61. Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103(2):211-225.
62. Schlessinger J. 2004. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306(5701):1506-1507. (Pubitemid 39564935)
63. Sévère N, Miraoui H, Marie PJ. 2011. The CBL mutant G306E enhances osteogenic differentiation in human mesenchymal stromal cells in part by decreased CBL-mediated PDGFRα and FGFR2 ubiquitination. J Biol Chem 286(27):24443-24445.
64. Shukla V, Coumoul X, Wang RH, Kim HS, Deng CX. 2007. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet 39(9):1145-1150. (Pubitemid 47340648)
65. Su N, Du X, Chen L. 2008. FGF signaling: Its role in bone development and human skeleton diseases. Front Biosci 13:2842-2865. (Pubitemid 351589202)
66. Su N, Sun Q, Li C, Lu X, Qi H, Chen S, Yang J, Du X, Zhao L, He Q, Jin M, Shen Y, Chen D, Chen L. 2010. Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis. Hum Mol Genet 19(7):1199-1210.
67. Suzuki H, Suda N, Shiga M, Kobayashi Y, Nakamura M, Iseki S, Moriyama K. 2011. Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts. J Cell Physiol. doi: 10.1002/jcp.24021.
68. Tanimoto Y, Yokozeki M, Hiura K, Matsumoto K, Nakanishi H, Matsumoto T, Marie PJ, Moriyama K. 2004. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem 279(44):45926-45934. (Pubitemid 39491585)
69. Teplyuk NM, Haupt LM, Ling L, Dombrowski C, Mun FK, Nathan SS, Lian JB, Stein JL, Stein GS, Cool SM, van Wijnen AJ. 2009. The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor/proteoglycan signaling axis in osteoblasts. J Cell Biochem 107(1):144-154.
70. Warren SM, Brunet LJ, Harland RM, Economides AN, Longaker MT. 2003. The BMP antagonist noggin regulates cranial suture fusion. Nature 422(6932):625-629. (Pubitemid 36460417)
71. White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, Fields J, Yu X, Shaw NJ, McLellan NJ, McKeown C, Fitzpatrick D, Yu K, Ornitz DM, Econs MJ. 2005. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76(2):361-367. (Pubitemid 40129563)
72. Wilkie AO. 2005. Bad bones, absent smell, selfish testes: The pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 16(2):187-203. (Pubitemid 40616116)
73. Wilkie AO. 2007. Cancer drugs to treat birth defects. Nat Genet 39(9):1057-1059. (Pubitemid 47340640)
74. Wohrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M, Muller M, Kinzel B, Thuery A, Brueggen J, Hynes NE, Sellers WR, Hofmann F, Graus-Porta D. 2011. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF- 23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res 26(10):2486-2497.
75. Wong ES, Lim J, Low BC, Chen Q, Guy GR. 2001. Evidence for direct interaction between Sprouty and Cbl. J Biol Chem 276(8): 5866-5875.
76. Xiao L, Liu P, Li X, Doetschman T, Coffin JD, Drissi H, Hurley MM. 2009. Exported 18-kDa isoform of fibroblast growth factor-2 is a critical determinant of bone mass in mice. J Biol Chem 284(5):3170-3182.
77. Xiao L, Sobue T, Esliger A, Kronenberg MS, Coffin JD, Doetschman T, Hurley MM. 2010. Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells. Bone 47(2):360-370.
78. Yang X, Webster JB, Kovalenko D, Nadeau RJ, Zubanova O, Chen PY, Friesel R. 2006. Sprouty genes are expressed in osteoblasts and inhibit fibroblast growth factor-mediated osteoblast responses. Calcif Tissue Int 78(4):233-240.
79. Yu K, Xu J, Liu Z, Sosic D, Shao J, Olson EN, Towler DA, Ornitz DM. 2003. Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development 130(13):3063-3074. (Pubitemid 36857252)
80. Yu HM, Jerchow B, Sheu TJ, Liu B, Costantini F, Puzas JE, Birchmeier W, Hsu W. 2005. The role of Axin2 in calvarial morphogenesis and craniosynostosis. Development 132(8): 1995-2005. (Pubitemid 40691787)
81. Zhou YX, Xu X, Chen L, Li C, Brodie SG, Deng CX. 2000. A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum Mol Genet 9(13):2001-2008. (Pubitemid 30642665)